Europe Oligonucleotide Synthesis Market worth USD 7.49 billion by 2030
The report "Europe Oligonucleotide Synthesis Market by Product (Drugs (ASO, siRNA), Synthesized Oligos (Product (Primers, Probes)), Type ((Custom, Predesigned), Reagents, Equipment), Application (Therapeutic, Research, Diagnostics) - Forecast to 2030" is projected to reach USD 7.49 billion by 2030 from USD 3.17 billion in 2025, at a CAGR of 18.7% during the forecast period of 2025 to 2030.
Browse 565 market data Tables and 45 Figures spread through 460 Pages and in-depth TOC on "Europe Oligonucleotide Synthesis Market by Product ((Drugs (ASO, siRNA), Synthesized Oligos (Product (Primers, Probes)), Type ((Custom, Predesigned), Reagents, Equipment), Application (Therapeutic, Research, Diagnostics) - Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/europe-oligonucleotide-synthesis-market-27129048.html
Several factors are driving the growth of the oligonucleotide synthesis market in Europe. The region has a strong base of pharmaceutical and biotechnology companies developing ASO, siRNA, and gene-editing therapies. This sustains steady demand for GMP-grade, high-purity oligonucleotides and continued spending on synthesis, purification, and quality testing. In addition, increasing approvals of oligonucleotide-based drugs across Europe are expanding usage in hospitals and specialty clinics. This is raising the need for reliable commercial supply, consistent batch quality, and scalable manufacturing capabilities.
By product, the oligonucleotide-based drugs segment accounted for the dominant market share in Europe in 2024.
Based on product, the oligonucleotide synthesis market in Europe is divided into oligonucleotide-based drugs, synthesized oligonucleotides, reagents & consumables, and equipment. In 2024, the oligonucleotide-based drugs segment held the dominant revenue share of the market in Europe. This is due to the high value of therapeutic manufacturing compared to research or diagnostic oligos. Oligonucleotide drugs require GMP-grade production, high purity, and strict quality control, which drives higher spending on synthesis, purification, and analytical testing. Demand for chemically modified and conjugated oligos is also increasing, raising the value per batch. Additionally, as more European programs progress from clinical to commercial stages, manufacturers are placing larger and recurring orders to ensure supply reliability and regulatory compliance.
By application, the therapeutic applications segment dominated the market in Europe in 2024.
By?????? application, the oligonucleotide synthesis market in Europe has been segmented into therapeutic applications, research applications, and diagnostic applications. The market was largely influenced by the therapeutic applications segment in 2024. Therapeutic programs entail the use of high-value, GMP-grade oligos, which are repeated in cycles throughout clinical trials and commercial supply. Besides, almost all therapeutic oligos require complicated chemical modifications and conjugations, which, in turn, elevate the synthesis effort and purification intensity.
Germany is expected to register the highest growth rate in the oligonucleotide synthesis market in Europe between 2025 and 2030.
By country, the market for oligonucleotide synthesis in Europe has been segregated into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany is expected to register the highest growth rate in this market, driven by the country’s strong concentration of pharmaceutical and biotechnology companies with active small-molecule and biologics pipelines. As a result, demand is increasing for advanced discovery platforms, screening technologies, and data-driven tools across early-stage research.
Key companies active in the oligonucleotide synthesis market in Europe include Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Eurofins Scientific (Luxembourg), OligoMaker ApS (Denmark), and Biolegio B.V. (Netherlands), along with other regional and global companies.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Europe Oligonucleotide Synthesis Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
